Latest Period
Q2 2026
Security Snapshot
Bicara Therapeutics Inc. - Common Stock (BCAX) Institutional Ownership
CUSIP: 055477103
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
169
Shares (Excl. Options)
72,108,896
Price
$29.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- BCAX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 72,108,896
- Total 13F value
- $2,129,518,435
- Portfolio coverage rank
- 0.01%
- Share change
- +2,063,091
- Value change
- +$61,880,521
- Number of holders
- 169
- Shares outstanding
- 66,062,813
- SEC-reported price per share
- $26.88
- Insider filing price
- $26.88
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BCAX - Bicara Therapeutics Inc. - Common Stock is tracked under CUSIP 055477103.
- 169 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 144 to 169 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,392,822,194 to $2,129,518,435.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 169 institutions filings for Q2 2026.
Security key
055477103
Latest holder period
Q2 2026
13F holders
169
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
BCAX full holder history
Bicara Therapeutics Inc. SEC filings
Bicara Therapeutics Inc. company facts
Bicara Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 055477103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
BCAX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12% | $123,100,386 | 7,279,739 | RA Capital Management, L.P. | 26 Feb 2026 | |||
| T. Rowe Price Investment Management, Inc. | 10% | +70% | $131,386,982 | +$67,012,079 | 6,605,780 | +104% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| Vestal Point Capital, LP | 8.3% | +26% | $120,109,500 | +$40,959,000 | 5,425,000 | +52% | Vestal Point Capital, LP | 31 Mar 2026 |
| Invus Global Management, LLC | 9.6% | $50,656,769 | 5,216,969 | Raymond Debbane | 30 Jun 2025 | |||
| Deep Track Capital, LP | 6.2% | +24% | $89,943,750 | +$29,058,750 | 4,062,500 | +48% | Deep Track Capital, LP | 31 Mar 2026 |
| BlackRock, Inc. | 5.4% | $104,991,886 | 3,536,271 | BlackRock, Inc. | 30 Jun 2026 | |||
| Janus Henderson Group Ltd. | 4.8% | -6% | $94,147,435 | -$4,993,947 | 3,171,015 | -5% | JANUS HENDERSON GROUP Ltd. | 30 Jun 2026 |
| Red Tree GP, LLC | 4.8% | $70,195,069 | 3,170,509 | Red Tree GP, LLC | 31 Mar 2026 | |||
| FMR LLC | 3.2% | -48% | $46,514,568 | -$27,592,949 | 2,100,929 | -37% | FMR LLC | 31 Mar 2026 |
As of 30 Jun 2026, 169 institutional investors reported holding 72,108,896 shares of Bicara Therapeutics Inc. - Common Stock (BCAX). This represents 109% of the company’s total 66,062,813 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
94%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 7,255,993 | 0% | 1.9% | $215,430,432 |
| T. Rowe Price Investment Management, Inc. | 9.6% | 6,338,487 | -4% | 0.12% | $188,190,000 |
| Siren, L.L.C. | 8.5% | 5,602,970 | -3.4% | 3.4% | $166,352,179 |
| Vestal Point Capital, LP | 7.9% | 5,250,000 | -3.2% | 3.6% | $155,872,500 |
| Deep Track Capital, LP | 6.2% | 4,100,000 | +0.92% | 1.8% | $121,729,000 |
| BlackRock, Inc. | 5.8% | 3,848,090 | +35% | 0% | $114,249,784 |
| Jupiter Topco LLC | 4.8% | 3,171,015 | 0% | 0.04% | $93,957,174 |
| RED TREE MANAGEMENT, LLC | 4.8% | 3,163,517 | -0.22% | 64% | $93,924,820 |
| TPG GP A, LLC | 4.6% | 3,010,425 | 0% | 1.8% | $89,379,518 |
| Royalty Pharma Sub-Manager, LLC | 3.6% | 2,388,150 | 0% | 25% | $60,611,247 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 2,216,639 | +25% | 0% | $65,812,012 |
| STATE STREET CORP | 3.1% | 2,048,920 | +44% | 0% | $60,832,435 |
| FRANKLIN RESOURCES INC | 3% | 1,951,892 | +20% | 0.01% | $57,951,672 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.9% | 1,904,248 | +38% | 0.01% | $56,538,000 |
| FMR LLC | 2.9% | 1,893,070 | -9.9% | 0% | $56,205,248 |
| Omega Fund Management, LLC | 2.8% | 1,822,150 | -24% | 29% | $54,099,634 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,162,635 | +40% | 0% | $34,525,388 |
| JPMORGAN CHASE & CO | 1.5% | 1,015,965 | +473% | 0% | $29,808,414 |
| Jones Hill Capital LP | 1.4% | 892,621 | -29% | 5.6% | $26,501,917 |
| ACORN CAPITAL ADVISORS, LLC | 0.97% | 643,381 | -0% | 5.2% | $19,102,000 |
| Aisling Capital Management LP | 0.86% | 568,919 | 0% | 3.6% | $16,891,205 |
| Palo Alto Investors LP | 0.83% | 550,408 | 0% | 2.3% | $16,341,614 |
| Rock Springs Capital Management LP | 0.81% | 535,286 | +9.4% | 0.78% | $15,892,641 |
| GOLDMAN SACHS GROUP INC | 0.79% | 520,567 | -6.9% | 0% | $15,455,635 |
| D. E. Shaw & Co., Inc. | 0.75% | 498,193 | +80% | 0.01% | $14,791,350 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 72,108,896 | $2,129,518,435 | +$61,880,521 | $29.69 | 169 |
| 2026 Q1 | 70,082,929 | $1,392,822,194 | +$187,858,254 | $19.89 | 144 |
| 2025 Q4 | 57,096,026 | $960,809,484 | +$119,906,754 | $16.83 | 141 |
| 2025 Q3 | 49,994,786 | $789,088,187 | +$2,780,392 | $15.79 | 112 |
| 2025 Q2 | 51,165,684 | $475,330,436 | -$6,689,372 | $9.29 | 105 |
| 2025 Q1 | 48,567,553 | $633,357,650 | +$9,523,679 | $13.03 | 92 |
| 2024 Q4 | 46,709,070 | $813,618,424 | +$73,899,338 | $17.42 | 84 |
| 2024 Q3 | 36,408,664 | $927,393,381 | +$849,110,088 | $25.47 | 69 |